NABI PRESENTS DATA FOR ALTASTAPH STUDY

Nabi Biopharmaceuticals has reported data showing that patients treated with Altastaph (staphylococcus aureus immune globulin intravenous) had a shorter duration of bacteremia (bloodstream infections) and fever versus the placebo group. As previously reported, the treated group also left the hospital sooner. Altastaph is an investigational human antibody-based product in development to treat adult in-hospital patients with persistent S. aureus bacteremia.

In this study, there was a 36 percent reduction in median time from administration of the study drug to hospital discharge in the Altastaph-treated patients as compared to the placebo-treated patients (nine days in the Altastaph group versus 14 days in the placebo group). This substantial reduction in the length of hospital stays for the Altastaph-treated group indicates that S. aureus antibodies provided by Altastaph could be associated with considerable medical as well as health economic benefit in the treatment of persistent S. aureus infections.

The study results also showed a shorter duration of bacteremia (one day in the Altastaph group versus two days in the placebo group) and fever (two days in the Altastaph group versus seven days in the placebo group).